-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Since September, the pharmaceutical sector has been rising.
According to Flush data, from September 3 to September 22, the Shenwan Pharmaceutical Biological Industry Index has risen by 6.
56%
.
From the perspective of individual stocks, from September 3 to September 22, 254 of the 394 pharmaceutical stocks rose, accounting for more than 60%
.
Meanwhile, 32 stocks rose more than 20% during the period
.
Among them, Tianyu shares, Stellite, Tiger Pharmaceuticals, Medicilon and other stocks rose by more than 30%; Tai'antang, Sunshine Nuohe rose by more than 40%; and Will Pharmaceuticals rose by 66.
15%
.
Below, the author will take you to focus on the development of Will Pharmaceutical, Tai'antang, Sunshine Nuohe
.
Weir Pharmaceuticals Weir Pharmaceuticals belongs to the pharmaceutical manufacturing industry.
Its main businesses are synthetic lubricating base oils, pharmaceutical excipients, and others, accounting for 64.
36%, 30.
62%, and 4.
14% of its revenue, respectively
.
In the first half of this year, Will Pharmaceuticals increased development and expanded the supply of pharmaceutical excipients, which brought good returns to the company
.
The data shows that in the first half of the year, the sales volume of Weir Pharmaceutical's pharmaceutical excipient products increased by 2.
31% year-on-year, and the sales increased by 20.
16% year-on-year to 130 million yuan
.
Among them, the sales volume of injectable drug supplements in the first half of the year increased by 25% year-on-year, the sales price increased by 19% year-on-year, and the sales volume was 60.
77 million yuan
.
It is understood that on September 7, Will Pharmaceutical also issued the "Announcement on Trial Production of Fundraising Projects"
.
The announcement shows that some devices of the "20,000t/a Injection Pharmaceutical Excipients and General Pharmaceutical Excipients Industrial Base Project" have completed construction, installation and commissioning, and have entered the trial production stage
.
The net profit is expected to exceed 200 million yuan after the fundraising project reaches production
.
In addition, at the beginning of September, Will Pharmaceutical also obtained the registration number of squalene for injection, which is the specification of domestic injection-grade pharmaceutical excipients, and is expected to contribute more than 250 million yuan in net profit each year
.
Sunshine Novo Sunshine Novo is one of the earliest CRO companies in China to provide drug R&D services
.
As an external resource that pharmaceutical manufacturing enterprises can borrow, the company can quickly organize a highly specialized and experienced research team in a short period of time after accepting the entrustment of customers, thereby helping pharmaceutical manufacturing enterprises to accelerate the progress of drug research and development, Reduce drug development costs and enable high-quality research
.
According to the semi-annual report data released by the company, in the first half of this year, Sunshine Nuohe achieved a year-on-year increase of 43.
94% in operating income to 224 million yuan; its net profit increased by 44.
35% year-on-year to 58.
9652 million yuan
.
Recently, Sunshine Nuohe said in answering questions from investors that through the successive implementation of fundraising projects, the company is gradually improving the pre-clinical and clinical research and development chain of various innovative drugs, and improving the comprehensive research and development service capabilities of new drugs
.
The company's management has been discussing and demonstrating the feasibility of GLP-related business expansion, and it is not ruled out that it will deploy GLP-qualified experimental sites in the future
.
Tai'an Tang Tai'an Tang has a history of 500 years; Qilin Pill is a national second-class Chinese medicine protected variety, and its production skills have won the national intangible cultural heritage; the traditional skin disease field includes Shezhishenhuang ointment, anti-inflammatory and ringworm wet ointment, and pruritus , Jiedu burn cream, etc.
; Xinbao Pills are the main products of cardiovascular and cerebrovascular categories
.
The company keeps pace with the times, rises with the trend, rapidly transforms and develops into a modern high-tech enterprise, upgrades the intelligent high-tech of traditional Chinese medicine, and builds 72 fully automatic production lines, intelligent extraction workshops, and unmanned production workshops; Pharmaceutical e-commerce brand; the company focuses on new technologies of modern biomedicine, and its subsidiary, Giansi Gene, is committed to the research and development of genetic testing, gene therapy and other technologies
.
From the perspective of financial status, Tai'an Tang's 2021 interim report shows that the company's main income is 1.
239 billion yuan; the net profit attributable to the parent is 520 million yuan, a year-on-year increase of 1865.
72%
.
According to Flush data, from September 3 to September 22, the Shenwan Pharmaceutical Biological Industry Index has risen by 6.
56%
.
From the perspective of individual stocks, from September 3 to September 22, 254 of the 394 pharmaceutical stocks rose, accounting for more than 60%
.
Meanwhile, 32 stocks rose more than 20% during the period
.
Among them, Tianyu shares, Stellite, Tiger Pharmaceuticals, Medicilon and other stocks rose by more than 30%; Tai'antang, Sunshine Nuohe rose by more than 40%; and Will Pharmaceuticals rose by 66.
15%
.
Below, the author will take you to focus on the development of Will Pharmaceutical, Tai'antang, Sunshine Nuohe
.
Weir Pharmaceuticals Weir Pharmaceuticals belongs to the pharmaceutical manufacturing industry.
Its main businesses are synthetic lubricating base oils, pharmaceutical excipients, and others, accounting for 64.
36%, 30.
62%, and 4.
14% of its revenue, respectively
.
In the first half of this year, Will Pharmaceuticals increased development and expanded the supply of pharmaceutical excipients, which brought good returns to the company
.
The data shows that in the first half of the year, the sales volume of Weir Pharmaceutical's pharmaceutical excipient products increased by 2.
31% year-on-year, and the sales increased by 20.
16% year-on-year to 130 million yuan
.
Among them, the sales volume of injectable drug supplements in the first half of the year increased by 25% year-on-year, the sales price increased by 19% year-on-year, and the sales volume was 60.
77 million yuan
.
It is understood that on September 7, Will Pharmaceutical also issued the "Announcement on Trial Production of Fundraising Projects"
.
The announcement shows that some devices of the "20,000t/a Injection Pharmaceutical Excipients and General Pharmaceutical Excipients Industrial Base Project" have completed construction, installation and commissioning, and have entered the trial production stage
.
The net profit is expected to exceed 200 million yuan after the fundraising project reaches production
.
In addition, at the beginning of September, Will Pharmaceutical also obtained the registration number of squalene for injection, which is the specification of domestic injection-grade pharmaceutical excipients, and is expected to contribute more than 250 million yuan in net profit each year
.
Sunshine Novo Sunshine Novo is one of the earliest CRO companies in China to provide drug R&D services
.
As an external resource that pharmaceutical manufacturing enterprises can borrow, the company can quickly organize a highly specialized and experienced research team in a short period of time after accepting the entrustment of customers, thereby helping pharmaceutical manufacturing enterprises to accelerate the progress of drug research and development, Reduce drug development costs and enable high-quality research
.
According to the semi-annual report data released by the company, in the first half of this year, Sunshine Nuohe achieved a year-on-year increase of 43.
94% in operating income to 224 million yuan; its net profit increased by 44.
35% year-on-year to 58.
9652 million yuan
.
Recently, Sunshine Nuohe said in answering questions from investors that through the successive implementation of fundraising projects, the company is gradually improving the pre-clinical and clinical research and development chain of various innovative drugs, and improving the comprehensive research and development service capabilities of new drugs
.
The company's management has been discussing and demonstrating the feasibility of GLP-related business expansion, and it is not ruled out that it will deploy GLP-qualified experimental sites in the future
.
Tai'an Tang Tai'an Tang has a history of 500 years; Qilin Pill is a national second-class Chinese medicine protected variety, and its production skills have won the national intangible cultural heritage; the traditional skin disease field includes Shezhishenhuang ointment, anti-inflammatory and ringworm wet ointment, and pruritus , Jiedu burn cream, etc.
; Xinbao Pills are the main products of cardiovascular and cerebrovascular categories
.
The company keeps pace with the times, rises with the trend, rapidly transforms and develops into a modern high-tech enterprise, upgrades the intelligent high-tech of traditional Chinese medicine, and builds 72 fully automatic production lines, intelligent extraction workshops, and unmanned production workshops; Pharmaceutical e-commerce brand; the company focuses on new technologies of modern biomedicine, and its subsidiary, Giansi Gene, is committed to the research and development of genetic testing, gene therapy and other technologies
.
From the perspective of financial status, Tai'an Tang's 2021 interim report shows that the company's main income is 1.
239 billion yuan; the net profit attributable to the parent is 520 million yuan, a year-on-year increase of 1865.
72%
.
